MedPath

Mifepristone as a single agent for second trimester termination of pregnancy in women with previous caesarea

Phase 4
Conditions
Health Condition 1: O048- (Induced) termination of pregnancywith other and unspecified complications
Registration Number
CTRI/2023/06/053424
Lead Sponsor
Diksha Malhotra
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

All women with previous caesarean section requiring termination of pregnancy between 14-24 weeks

1) 18 years or older

2) Singleton gestation

3) Late miscarriage/inevitable abortion between 14-20 weeks

4) Pregnancy getting terminated for lethal fetal anomalies/medical or social reasons between 14-24 weeks(under MTP Amendment Act,2021)

5) Intra uterine fetal death (IUFD)/previable premature rupture of membranes(PPROM)between 20-24 weeks

Exclusion Criteria

1) Known contraindication to mifepristone(chronic adrenal failure, long term steroid treatment,concurrent anticoagulation therapy,bleeding disorders,inherited porphyrias)

2) Known contraindication to misoprostol(renal impairment,inflammatory bowel disease, pre existing heart disease,unexplained vaginal bleeding,known allergies)

3) Previous myomectomy or nature of scar unknown or previous history of uterine rupture

4) Severe anaemia

5) Evidence of sepsis

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Proportion of women having successful induction of abortionTimepoint: After 24 hours of completion of regimen
Secondary Outcome Measures
NameTimeMethod
1) Induction to abortion time in hours <br/ ><br>2) Rate of complete abortion <br/ ><br>3) Failed abortion rate <br/ ><br>4) Number of women having adverse events <br/ ><br>5) Maternal side effects like vomiting, diarrhoea, shivering, pyrexia <br/ ><br>6) Pregnancy related readmission within 30 daysTimepoint: After 24 hours of completion of regimen
© Copyright 2025. All Rights Reserved by MedPath